ALLERGAN's NDA FILING FOR BETA BLOCKER LEVOBUNOLOL MAKES THREE NDAs
Executive Summary
ALLERGAN's NDA FILING FOR BETA BLOCKER LEVOBUNOLOL MAKES THREE NDAs filed by the SmithKline Beckman subsidiary in the past four months, according to SmithKline's just-released annual report for 1983. The levobunolol NDA for the treatment of glaucoma was filed with FDA "in early 1984," the report notes. Internatl. filings for the beta blocker, licensed from Warner-Lambert, "are underway," the annual report adds. In addition to the levobunolol NDA, SmithKline reports, Allergan filed NDAs in December for two other products: an unnamed steroid/antibiotic combination and a higher dosage form of the steroid anti-inflammatory FML. SmithKline's Allergan eye and skin care business, which includes Herbert Labs, continues to be one of several steady growth business segments for the diversified healthcare firm. In 1983, Allergan's sales jumped nearly 17% to $202 mil. after a 25% sales gain the previous year. The firm's dermatology div., Herbert Labs, "completed its second year as a separate operating unit with good growth prospects in Rx dermatology," the annual report notes. As part of the div.'s move out of the OTC product area and into the Rx dermatology market, Herbert Labs signed an agreement last October with Sandoz subsidiary Dorsey to exchange Herbert's Eclipse suncare product line for Dorsey's Gris-PEG Rx anti-fungal. While Herbert Labs in marketing Gris-PEG, an oral form of griseofulvin, Allergan is working with former subsidiary Nelson R&D on a topical form of griseofulvin (Griseoderm) using Nelson's Azone transdermal technology. An NDA for Grisoderm was filed with FDA in 1981 and is still pending. Herbert Labs is also developing another anti-fungal product licensed from Sandoz called naftifine. SmithKline noted that an NDA for the broad spectrum anti-fungal "is expected to be filed by mid-1984."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth